CMO
BiomX
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Sailaja Puttagunta, MD, Chief Medical Officer, BiomX Inc
Dr. Puttagunta ihas been the Chief Medical Officer of BiomX since December 2018. Prior to joining BiomX, Dr. Puttagunta served as Vice President, Development at Iterum Therapeutics plc, a clinical stage pharmaceutical company developing antibiotics against multi-drug resistant pathogens, from January 2016 to December 2018. Prior to Iterum, Dr. Puttagunta served as VP, Medical Affairs for Anti-infectives at Allergan plc from January 2015 to January 2016 and was the Vice President of Development and Medical Affairs at Durata Therapeutics prior to that where she was responsible for the development of the antibiotic, dalbavancin. Prior to joining Durata, Dr. Puttagunta led teams within clinical development and medical affairs on various antibiotic compounds at Pfizer Inc. Dr. Puttagunta graduated from Gandhi Medical College in Hyderabad, India and completed her residency in Internal Medicine and a fellowship in Infectious Diseases at Yale University School of Medicine. She also holds an M.S. in Biochemistry from the New York University School of Medicine.